Understanding the PROMPT-AF Trial: A Breakthrough in Persistent AF Management The PROMPT-AF trial marks an important step forward in our understanding of how to manage persistent atrial fibrillation (AF) more effectively. Conducted as an investigator-initiated, multicenter, open-label randomized trial, PROMPT-AF … Read More
Electrophysiology
CASTLE HTx Trial: Ablation in HF and AFib
The CASTLE HTx trial, as published in the New England Journal of Medicine in 2023, was a single-center, open-label trial that aimed to determine the potential therapeutic effect of catheter ablation for symptomatic atrial fibrillation (AF) in patients with end-stage … Read More
NOAH-AFNET 6 Trial: Edoxaban in AHRE
The NOAH-AFNET 6 trial, as outlined in a groundbreaking study from the New England Journal of Medicine in 2023, represents a significant advancement in our understanding of atrial fibrillation management. This study scrutinized the efficacy of edoxaban, a novel oral … Read More
VITAL-AF Trial: Screening for AFib
VITAL-AF Trial Summary The VITAL-AF trial aimed to determine whether point-of-care screening with a handheld single-lead ECG device during primary care visits increases the diagnosis of atrial fibrillation (AF) in older adults. The study randomized 16 primary care clinics in … Read More
WRAP-IT Trial: Utilizing Antibiotic-Eluting Envelopes to Reduce Infections After Cardiac Device Implantation
WRAP-IT Trial Summary Infections following the placement of cardiac implantable electronic devices (CIEDs) can lead to significant morbidity and mortality. Although preoperative antibiotics are a standard prophylactic strategy, evidence for other preventive approaches is limited. The WRAP-IT trial sought to … Read More
MADIT-CRT Trial Summary: CRT in HF
2009 MADIT-CRT TRIAL Cardiac-Resynchronization Therapy for the prevention of heart-failure events multicenter, open-label, randomized controlled trial Objective: To determine whether cardiac-resynchronization therapy with implantable cardioverter-defibrillator (CRT-ICD) would reduce the risk of death or heart-failure events in M patients with mild … Read More